Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

UGN-102 Achieves 82.3% Duration of Response at 12 Months for LG-IR-NMIBC

January 21, 2025

Sasanlimab in Combination with BCG Improves EFS in Patients with BCG-Naïve, High-Risk NMIBC

January 15, 2025

Adjuvant Libtayo® (cemiplimab) Significantly Improves DFS After Surgery in High-Risk CSCC in Ph 3 Trial

January 15, 2025

Positive Update provided on Ph 2a Arm of IMM-1-104 in Combination with Modified FOLFIRINOX for 1L Pancreatic Cancer

January 15, 2025

RYBREVANT® (amivantamab-vmjw) + LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in OS versus osimertinib

January 15, 2025

New Sarclisa SC formulation met co-primary endpoints in the IRAKLIA Ph 3 study in multiple myeloma

January 15, 2025

Positive Initial Clinical Data from Ph 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660) Announced; Expansion in TNBC Initiated

January 15, 2025

Positive Topline Results from China GC/GEJ Ph 2 Trial of Claudin18.2 CAR-T (Satri-cel) announced

December 31, 2024

Positive Interim Ph 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Announced

December 26, 2024

FAILED TRIAL: Ph 3 Bridging Trial in China in Patients with R/R AML did not demonstrate favorable benefit for uproleselan

December 26, 2024

Initial clinical results from ongoing KYANITE-1 study of inhaled KB707 in patients with solid tumors of the lung announced

December 25, 2024

Safety Review Committee Approval of Opening 3rd Cohort and Preliminary Results from 1st Cohort in Ph 1 TTX-MC138 Trial Announced

December 25, 2024

FAILED TRIAL: FIRST trial of Jemperli (dostarlimab) + chemo and Zejula maintenance +/- avastin met primary endpoint of PFS but not OS in 1L advanced ovarian cancer

December 25, 2024

CAN-2409 Achieved Primary Endpoint in Ph 3 Prostate Cancer Trial, Showing Significantly Improved DFS

December 18, 2024

Data Updates Across Zelenectide Pevedotin Program Announced

December 18, 2024

Positive Initial Data from LOTIS-7 Trial of ZYNLONTA® in Combination with Bispecific Antibody in Patients with R/R LBCL Announced

December 18, 2024

Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V) presented

December 18, 2024

Continued Strong Improvement in OS Data from Ph 2 OVATION 2 Study of IMNN-001 Announced

December 18, 2024

Positive Initial Data from First-line RAS-mutated mCRC Ph 2 CRDF-004 trial evaluating onvansertib + SoC Announced

December 18, 2024

Data shows strong OS, PFS, and durability from combination of efti + pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1

December 18, 2024

Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph 1 Gynecologic Expansion Clinical Trial Announced

December 18, 2024

Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive NMIBC

December 10, 2024

Ph 3 POD1UM-304 trial of Retifanlimab (Zynyz®) + Chemo met primary endpoint of OS and all secondary endpoints in patients with 1L metastatic NSCLC

December 10, 2024

Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

December 10, 2024

Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFRMutated NSCLC in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis

December 10, 2024
Page1 … Page4 Page5 Page6 Page7 Page8 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.